A detailed history of Voya Investment Management LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 75,112 shares of RXRX stock, worth $452,925. This represents 0.0% of its overall portfolio holdings.

Number of Shares
75,112
Previous 68,691 9.35%
Holding current value
$452,925
Previous $515,000 4.08%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.92 - $8.6 $38,012 - $55,220
6,421 Added 9.35%
75,112 $494,000
Q2 2024

Dec 03, 2024

SELL
$7.35 - $10.05 $47,194 - $64,531
-6,421 Reduced 8.55%
68,691 $515,000
Q2 2024

Aug 14, 2024

SELL
$7.35 - $10.05 $423,367 - $578,890
-57,601 Reduced 45.61%
68,691 $515,000
Q1 2024

Dec 06, 2024

BUY
$9.13 - $15.52 $467,273 - $794,313
51,180 Added 68.14%
126,292 $1.26 Million
Q1 2024

May 15, 2024

BUY
$9.13 - $15.52 $406,741 - $691,416
44,550 Added 54.5%
126,292 $1.26 Million
Q4 2023

Feb 14, 2024

SELL
$5.09 - $10.79 $2,819 - $5,977
-554 Reduced 0.67%
81,742 $805,000
Q3 2023

Nov 14, 2023

BUY
$6.59 - $15.86 $181,982 - $437,973
27,615 Added 50.5%
82,296 $629,000
Q2 2023

Aug 14, 2023

BUY
$4.56 - $9.94 $9,466 - $20,635
2,076 Added 3.95%
54,681 $408,000
Q3 2022

Nov 14, 2022

BUY
$7.83 - $13.6 $10,374 - $18,020
1,325 Added 2.58%
52,605 $560,000
Q2 2022

Aug 15, 2022

BUY
$5.04 - $9.26 $258,451 - $474,852
51,280 New
51,280 $417,000
Q1 2022

May 16, 2022

SELL
$6.16 - $18.03 $263,962 - $772,603
-42,851 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$16.14 - $21.86 $509,878 - $690,579
31,591 Added 280.56%
42,851 $734,000
Q3 2021

Nov 15, 2021

BUY
$19.03 - $41.33 $58,783 - $127,668
3,089 Added 37.8%
11,260 $259,000
Q2 2021

Aug 16, 2021

BUY
$18.0 - $37.42 $147,078 - $305,758
8,171 New
8,171 $298,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.09B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.